ES517444A0 - Procedimiento para obtener medicamentos altamente solubles por atomizacion en presencia de un estabilizante y un agente inhibidor de formacion de cristales. - Google Patents

Procedimiento para obtener medicamentos altamente solubles por atomizacion en presencia de un estabilizante y un agente inhibidor de formacion de cristales.

Info

Publication number
ES517444A0
ES517444A0 ES517444A ES517444A ES517444A0 ES 517444 A0 ES517444 A0 ES 517444A0 ES 517444 A ES517444 A ES 517444A ES 517444 A ES517444 A ES 517444A ES 517444 A0 ES517444 A0 ES 517444A0
Authority
ES
Spain
Prior art keywords
atomization
stabilizer
procedure
crystal formation
inhibiting agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES517444A
Other languages
English (en)
Spanish (es)
Other versions
ES8505249A1 (es
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Elan Corp PLC
Original Assignee
Elan Corp PLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elan Corp PLC filed Critical Elan Corp PLC
Publication of ES8505249A1 publication Critical patent/ES8505249A1/es
Publication of ES517444A0 publication Critical patent/ES517444A0/es
Granted legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cephalosporin Compounds (AREA)
  • Saccharide Compounds (AREA)
ES517444A 1982-04-19 1982-11-17 Procedimiento para obtener medicamentos altamente solubles por atomizacion en presencia de un estabilizante y un agente inhibidor de formacion de cristales. Granted ES517444A0 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR8206646A FR2525108B1 (fr) 1982-04-19 1982-04-19 Medicaments a haut degre de solubilite et procede pour leur obtention

Publications (2)

Publication Number Publication Date
ES8505249A1 ES8505249A1 (es) 1985-05-16
ES517444A0 true ES517444A0 (es) 1985-05-16

Family

ID=9273120

Family Applications (1)

Application Number Title Priority Date Filing Date
ES517444A Granted ES517444A0 (es) 1982-04-19 1982-11-17 Procedimiento para obtener medicamentos altamente solubles por atomizacion en presencia de un estabilizante y un agente inhibidor de formacion de cristales.

Country Status (18)

Country Link
US (2) US4610875A (en:Method)
JP (1) JPS58183615A (en:Method)
AR (1) AR230183A1 (en:Method)
AT (1) AT389813B (en:Method)
AU (1) AU555579B2 (en:Method)
BE (1) BE894942A (en:Method)
CA (1) CA1225029A (en:Method)
CH (1) CH655003A5 (en:Method)
DE (1) DE3241097A1 (en:Method)
ES (1) ES517444A0 (en:Method)
FR (1) FR2525108B1 (en:Method)
GB (1) GB2119784B (en:Method)
IE (1) IE54084B1 (en:Method)
IT (1) IT1153099B (en:Method)
LU (1) LU84468A1 (en:Method)
NL (1) NL8204461A (en:Method)
PT (1) PT75867B (en:Method)
SE (1) SE8206697L (en:Method)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2525108B1 (fr) * 1982-04-19 1989-05-12 Elan Corp Ltd Medicaments a haut degre de solubilite et procede pour leur obtention
JPS60139688A (ja) * 1983-12-28 1985-07-24 Tokyo Tanabe Co Ltd 無定形ジヒドロピリジン粉末製剤
EP0214092A1 (en) * 1985-08-08 1987-03-11 Ciba-Geigy Ag Enhanced absorption of psychoactive 2-aryl-pyrazolo quinolines as a solid molecular dispersion in polyvinylpyrrolidone
US4798725A (en) * 1986-06-16 1989-01-17 Norwich Eaton Pharmaceuticals, Inc. Sustained release capsule
US4772473A (en) * 1986-06-16 1988-09-20 Norwich Eaton Pharmaceuticals, Inc. Nitrofurantoin dosage form
US4832953A (en) * 1987-08-13 1989-05-23 Alza Corporation Method for preventing the formation of a crystalline hydrate in a dispersion of a liquid in a monaqueous matrix
WO1991007385A1 (en) * 1989-11-18 1991-05-30 Schering Agrochemicals Limited Preparation of propenoic acid derivatives
IT1242642B (it) * 1990-04-17 1994-05-16 Alfa Wassermann Spa Formulazioni iniettabili contenenti naproxen sale sodico.
JPH0648937A (ja) * 1992-04-07 1994-02-22 Seitai Kagaku Kenkyusho:Kk 経口投与に適する薬剤およびその製造方法
US5512300A (en) * 1992-09-15 1996-04-30 Warner-Lambert Company Prevention of ibuprofen from forming low melting eutectics with other therapeutic agents in solid dosage forms
FR2722984B1 (fr) * 1994-07-26 1996-10-18 Effik Lab Procede de preparation de formes pharmaceutiques seches et les compositions pharmaceutiques ainsi realisees
US5994348A (en) 1995-06-07 1999-11-30 Sanofi Pharmaceutical compositions containing irbesartan
BE1009856A5 (fr) * 1995-07-14 1997-10-07 Sandoz Sa Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule.
US5686133A (en) * 1996-01-31 1997-11-11 Port Systems, L.L.C. Water soluble pharmaceutical coating and method for producing coated pharmaceuticals
WO1997034601A1 (fr) * 1996-03-18 1997-09-25 Eisai Co., Ltd. Compositions medicamenteuses a solubilite amelioree
US6066339A (en) * 1997-10-17 2000-05-23 Elan Corporation, Plc Oral morphine multiparticulate formulation
US6086915A (en) * 1998-04-01 2000-07-11 Bioresponse L.L.C. Compositions and methods of adjusting steroid hormone metabolism through phytochemicals
TR200100172T2 (tr) * 1998-07-20 2001-05-21 Smithkline Beecham Corporation Oral katı doz formunda eprosartan içeren biyolojik bakımdan kuvvetlendirilmiş formülasyonlar
WO2000020033A1 (en) * 1998-10-05 2000-04-13 Eisai Co., Ltd. Tablets immediately disintegrating in the oral cavity
CA2359945C (en) * 1999-11-12 2011-04-26 Abbott Laboratories Inhibitors of crystallization in a solid dispersion
US7364752B1 (en) 1999-11-12 2008-04-29 Abbott Laboratories Solid dispersion pharamaceutical formulations
JP2004500358A (ja) * 1999-12-08 2004-01-08 ファルマシア　コーポレイション バイオアベイラビリティーが増加した固体状態のセレコキシブ
KR100558239B1 (ko) 1999-12-23 2006-03-10 화이자 프로덕츠 인크. 증가된 약물 농도를 제공하는 제약학적 조성물
IL134701A0 (en) 2000-02-23 2001-04-30 J P M E D Ltd Homogeneous solid matrix containing vegetable proteins
DE10026698A1 (de) * 2000-05-30 2001-12-06 Basf Ag Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung
CA2412776C (en) 2000-06-16 2011-03-15 Mitsubishi Pharma Corporation Compositions controlling release ph range and/or speed
RU2271805C2 (ru) * 2000-10-24 2006-03-20 Адзиномото Ко., Инк. Препарат, содержащий натеглинид
CZ20033456A3 (en) * 2001-06-22 2004-07-14 Pfizer Products Inc. Pharmaceutical compositions comprising adsorbates of amorphous drug
BR0211028A (pt) * 2001-06-22 2004-06-15 Pfizer Prod Inc Solução aquosa, método para formação de associações de fármaco e polìmero, composições farmacêuticas, método para formação de uma composição farmacêutica e produto
EP1269994A3 (en) * 2001-06-22 2003-02-12 Pfizer Products Inc. Pharmaceutical compositions comprising drug and concentration-enhancing polymers
SI21223A (sl) * 2002-06-19 2003-12-31 Krka, Tovarna Zdravil, D.D., Novo Mesto Farmacevtska formulacija s stabiliziranim amorfnim donepezilijevim kloridom
US20040132771A1 (en) * 2002-12-20 2004-07-08 Pfizer Inc Compositions of choleseteryl ester transfer protein inhibitors and HMG-CoA reductase inhibitors
US20050152932A1 (en) * 2003-06-12 2005-07-14 Valery Normand Non-crystalline perfume or flavor delivery system
US8025899B2 (en) * 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
US8377952B2 (en) 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
US20050048112A1 (en) 2003-08-28 2005-03-03 Jorg Breitenbach Solid pharmaceutical dosage form
WO2006069159A2 (en) * 2004-12-20 2006-06-29 Dr. Reddy's Laboratories Ltd. Pharmaceutical compositions comprising amorphous benzimidazole compounds
EP2286800A1 (en) * 2005-04-11 2011-02-23 Abbott Laboratories Pharmaceutical compositions having improved dissolution profiles for poorly soluble drugs
WO2006119779A2 (en) * 2005-05-10 2006-11-16 Lifecycle Pharma A/S A pharmaceutical composition comprising an aldosterone antagonist in form of solid solution
EP1976486A1 (en) * 2006-01-27 2008-10-08 The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin A method of producing porous microparticles
PT103743B (pt) * 2007-05-16 2013-01-15 Hovione Farmaciencia S A Processo para preparar derivados de 21-disódio fosfato de pregnanos.
EP2358724B1 (en) * 2008-11-04 2012-08-29 Cipla Limited Tiotropium bromide having a low degree of crystallinity
PL2654731T3 (pl) * 2010-12-23 2017-01-31 AbbVie Deutschland GmbH & Co. KG Formulacje stałe o opóźnionym uwalnianiu na podstawie dyspersji stałych
WO2012164575A2 (en) 2011-05-27 2012-12-06 Hetero Research Foundation Amorphous ritonavir co-precipitated

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4151273A (en) * 1974-10-31 1979-04-24 The Regents Of The University Of California Increasing the absorption rate of insoluble drugs
JPS5163925A (ja) * 1974-11-30 1976-06-02 Kyowa Hakko Kogyo Kk Muteikeikuroramufuenikooruno seizoho
US4127647A (en) * 1975-04-08 1978-11-28 Meiji Seika Kaisha, Ltd. Process for preparation of stable amorphous macrolide antibiotic solids
JPS51118816A (en) * 1975-04-08 1976-10-19 Meiji Seika Kaisha Ltd A process for stabilizing non-crystalloidal solid
DE2634004B2 (de) * 1976-07-29 1978-08-10 Bernhard Dr. 8000 Muenchen Lippold Verfahren zur Beschleunigung der Auflösung und Verbesserung der Löslichkeit von schlechtlöslichen zur peroralen Verabreichung bestimmten Arzneistoffen
GB1579818A (en) * 1977-06-07 1980-11-26 Yamanouchi Pharma Co Ltd Nifedipine-containing solid preparation composition
EP0001247A1 (en) * 1977-09-14 1979-04-04 Kanebo, Ltd. Pharmaceutical preparation containing nifedipine and a method for producing the same.
US4128632A (en) * 1978-02-13 1978-12-05 Merck & Co., Inc. Solubilization of Rafoxanide
US4344934A (en) * 1978-11-20 1982-08-17 American Home Products Corporation Therapeutic compositions with enhanced bioavailability
JPS587609B2 (ja) * 1979-06-17 1983-02-10 フロイント産業株式会社 粉体薬剤のコ−テング法
JPS55139319A (en) * 1979-04-13 1980-10-31 Furointo Sangyo Kk Activation of drug soluble in alkali and acid
JPS6024768B2 (ja) * 1979-06-16 1985-06-14 フロイント産業株式会社 活性化薬剤の製法
DE3013839A1 (de) * 1979-04-13 1980-10-30 Freunt Ind Co Ltd Verfahren zur herstellung einer aktivierten pharmazeutischen zusammensetzung
CA1146866A (en) * 1979-07-05 1983-05-24 Yamanouchi Pharmaceutical Co. Ltd. Process for the production of sustained release pharmaceutical composition of solid medical material
JPS5948810B2 (ja) * 1980-03-22 1984-11-29 山之内製薬株式会社 ニカルジピン持続性製剤用組成物
JPS5646837A (en) * 1979-09-27 1981-04-28 Kowa Yakuhin Kogyo Kk Preparation of ibuprofen clathrate compound
JPS5655370A (en) * 1979-10-13 1981-05-15 Kyorin Pharmaceut Co Ltd Amorphous nicomol
US4327080A (en) * 1981-07-13 1982-04-27 E. R. Squibb & Sons, Inc. Novel Bendroflumethiazide formulations and method
FR2525108B1 (fr) * 1982-04-19 1989-05-12 Elan Corp Ltd Medicaments a haut degre de solubilite et procede pour leur obtention
DE3318649A1 (de) * 1983-05-21 1984-11-22 Bayer Ag, 5090 Leverkusen Zweiphasenformulierung

Also Published As

Publication number Publication date
IE54084B1 (en) 1989-06-07
GB2119784A (en) 1983-11-23
AU555579B2 (en) 1986-10-02
AT389813B (de) 1990-02-12
FR2525108A1 (fr) 1983-10-21
BE894942A (fr) 1983-05-09
DE3241097C2 (en:Method) 1989-04-13
ATA427282A (de) 1989-07-15
SE8206697L (sv) 1983-10-20
ES8505249A1 (es) 1985-05-16
JPS58183615A (ja) 1983-10-26
SE8206697D0 (sv) 1982-11-24
JPH0341444B2 (en:Method) 1991-06-24
NL8204461A (nl) 1983-11-16
GB2119784B (en) 1986-04-03
DE3241097A1 (de) 1983-10-20
US4769236A (en) 1988-09-06
IT1153099B (it) 1987-01-14
FR2525108B1 (fr) 1989-05-12
PT75867A (fr) 1982-12-01
AU9043182A (en) 1983-10-27
CA1225029A (en) 1987-08-04
IT8224368A0 (it) 1982-11-23
CH655003A5 (fr) 1986-03-27
IT8224368A1 (it) 1984-05-23
AR230183A1 (es) 1984-03-01
IE822610L (en) 1983-10-19
LU84468A1 (fr) 1983-06-13
PT75867B (fr) 1986-01-21
US4610875A (en) 1986-09-09

Similar Documents

Publication Publication Date Title
ES517444A0 (es) Procedimiento para obtener medicamentos altamente solubles por atomizacion en presencia de un estabilizante y un agente inhibidor de formacion de cristales.
IT8319295A0 (it) Schiume di alcooli altamente stabili e procedimenti di preparazione e di impiego di tali schiume.
GB2100605B (en) Bandage for administering drugs.
NL183920C (nl) Melk-voedingsprodukt en werkwijze voor de bereiding daarvan.
MY8500514A (en) The treatment of aqueous systems
NL7904347A (nl) Roestwerend middel voor waterige systemen en roest- werende smeermiddelsamenstelling.
IT7922028A0 (it) Polisaccaride e procedimento per produrlo.
NL970023I1 (nl) Medicamenten voor behandeling van oogontsteking.
NL7703434A (nl) Werkwijze voor de bereiding van stikstofhouden- de polysacchariden.
NL7713653A (nl) Werkwijze en inrichting voor de bereiding van fijne kristallen.
NL187268C (nl) Farmaceutische samenstelling tegen kanker en werkwijze voor de bereiding van de actieve stof.
FI823336A7 (fi) Menetelmä farmaseuttisesti aktiivisten bentsamidijohdannaisten valmistamiseksi.
NL174568C (nl) Werkwijze voor de bereiding van een tegen tumoren werkzaam polysaccharide en werkwijze voor de bereiding of vervaardiging van een farmaceutisch preparaat dat dat bevat.
IT7920952A0 (it) Procedimento di stampa offsetlitografica e apparecchiatura per la formazione di configurazioni o disegni continui.
NL187577C (nl) 3-acetoxy-9beta,11beta-epoxy-pregna-1,3,5-trienen, werkwijze voor de bereiding daarvan en werkwijze voor de bereiding van 6alfa-halogeen-pregna-1,4-dieen-3-onen.
NL7804582A (nl) Werkwijze voor de bereiding van 2-hydroxymethyl-3-hy- droxy-6-(1-hydroxy-2-tert. butylaminoethyl) pyridine en zuuradditiezouten daarvan.
JPS5369822A (en) Pharmaceutical agent
MX5719A (es) N-fenilsulfonil-n'-pirimidinil y -triazinil-ureas y procedimiento para su preparacion.
NL7811106A (nl) Werkwijze voor de bereiding van moranoline en n-methylmoranoline.
JPS54132563A (en) Corticosteroid antiiinflammatry drug
NL7904856A (nl) Staal en werkwijze voor de bereiding van staal.
ES295960Y (es) Dispositivo osmico para la descarga controlada de un agente.
NL7710762A (nl) Werkwijze voor de bereiding van s-3-chloor-1,2- -propaandiol alsmede gedoseerd farmaceutisch preparaat.
NL7714628A (nl) Gedisubstitueerde piperazinen, werkwijze voor de bereiding daarvan en dergelijke piperazinen bevattende geneesmiddelen.
ZA816321B (en) Ammoniomethyl compounds,processes for their manufacture,pharmaceutical preparations that contain these compounds,and the use of these compounds

Legal Events

Date Code Title Description
FD1A Patent lapsed

Effective date: 20011110